Public Health - Recommendations for Immunizations, Screenings, and Preventive Services - Pharmacist Administration and Required Health Insurance Coverage (The Vax Act)
HB637, the “Vax Act,” restructures Maryland’s approach to recommendations for immunizations, screenings, and other preventive services. It requires the Secretary of Health to issue recommendations based on evidence-based scientific and clinical guidance, including input from major medical organizations and federal public health bodies. For certain preventive services that are not immunizations and that do not already have federal support or an A/B rating from the U.S. Preventive Services Task Force, the Secretary must first hold at least a 30-day notice-and-comment period, obtain an analysis from the Maryland Health Care Commission, and cite the medical basis for the recommendation.
The bill also expands and updates pharmacist vaccination authority. Pharmacists may administer certain vaccines to individuals age 3 and older, including influenza, COVID-19, and vaccines used in a public health emergency, and may administer additional vaccines to individuals age 7 and older if recommended by the CDC’s advisory committee, approved or authorized by FDA, or recommended by the Secretary under the new state process. The bill keeps training, CPR, reporting, and patient-notification requirements in place, while tying pharmacist authority to the Secretary’s new recommendations.
On the insurance side, HB637 updates Maryland’s preventive-services coverage mandates so carriers must cover specified immunizations, screenings, and preventive services without cost-sharing, and it extends that coverage framework to recommendations issued by the Secretary under the new law. It also revises child wellness coverage requirements to incorporate Secretary-issued updates for childhood and adolescent immunizations, while preserving existing coverage for newborn screening, hearing screening, developmental screening, and related pediatric preventive care. The bill repeals obsolete pertussis vaccine provisions and sets an effective date of July 1, 2026, with application to policies and plans issued, delivered, or renewed on or after January 1, 2027.
The overall sentiment reflected in the voting history appears favorable to the bill, with both chambers ultimately passing it by comfortable margins. Two floor amendments were rejected in the House before third reading passage, suggesting some disagreement over details, but not enough to derail the measure. The bill’s final enactment indicates broad support for modernizing vaccine and preventive-service policy, though the rejected amendments show that some members sought changes to its scope or implementation.
The main points of contention appear to center on how much authority the Secretary of Health should have to update recommended services, and how closely state coverage rules should track evolving medical guidance. The bill tries to balance flexibility with procedural safeguards by requiring notice and comment and a commission analysis for certain non-immunization preventive services. Related concerns likely involve pharmacist scope of practice, insurance mandates, and whether state law should automatically incorporate future recommendations from state or federal health authorities.
HB637 repeals obsolete pertussis provisions and adds a new Health-General section directing the Secretary of Health to issue evidence-based recommendations for immunizations, screenings, and preventive services. It amends pharmacist practice law to allow administration of additional vaccines tied to Secretary recommendations, and it updates insurance statutes to require coverage of those Secretary-issued recommendations without cost-sharing, subject to the bill’s timing and existing federal-law framework. The bill also updates child wellness coverage requirements and applies to policies and plans issued, delivered, or renewed on or after January 1, 2027.
The bill appears to have been generally supported, as shown by successful third-reading passage in both chambers and final enactment by the Governor. The House rejected two floor amendments before passage, indicating some debate over the bill’s details, but the final votes suggest the core policy was broadly acceptable. Overall, the sentiment was favorable toward aligning state immunization and preventive-service policy with current medical guidance.
The likely areas of contention were the Secretary of Health’s new recommendation authority, the extent to which insurance coverage must follow those recommendations, and the expansion of pharmacist vaccination authority. The rejected floor amendments suggest some legislators wanted to alter the bill’s approach, though the record provided does not specify the exact objections. More broadly, the bill raises the familiar policy tension between public-health responsiveness and concerns about administrative discretion, insurance mandates, and pharmacy practice scope.